The value of fixed combination analgesics as exemplified by Thomapyrin®;ZWECKMASSIGKEIT FIXER ANALGETIKAKOMBINATIONEN AM BEISPIEL VON THOMAPYRIN®

Wiener Klinische Wochenschrift

Volumn 108, Issue 8, 1996, Pages 219-233

  Aicher, B ^a   Kraupp, O ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

acetyl salicylic acid; benefit risk ratio; caffeine; combination analgesics; paracetamol

Indexed keywords

ACETYLSALICYLIC ACID; APC; CAFFEINE; PARACETAMOL; ANALGESIC AGENT;

CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PAIN; REVIEW; RISK BENEFIT ANALYSIS; SELF MEDICATION; BLOOD; DRUG COMBINATION; GERMANY; PAIN ASSESSMENT; POSTMARKETING SURVEILLANCE; TREATMENT OUTCOME;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ASPIRIN; CAFFEINE; DRUG COMBINATIONS; GERMANY; HUMANS; PAIN; PAIN MEASUREMENT; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 0029692216     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Aicher B ( 1996) Dokumentation der unerwünschten Arzneimittelwirkungen und Stellungnahme zum Risikopotential von Thomapyrin® Schmerztabletten. Unveröff Bericht, Dr. Karl Thomae GmbH, Biberach
2. Anonymous (1986) Excedrin extra-strength analgesic efficacy and caffeine adjuvancy (overall synopsis): postoperative dental pain studies. Unpublished report (No 132-01-86 and No 132-02-86) Bristol-Myers Products, New York
3. Anonymous FDC-Reports (1995) Sept 4: 4-8
4. Anonymous (1995) Pharmakokinetics of paracetamol, acetyl salicylic acid and caffeine (Thomapyrin®) in healthy volunteers. Unpublished report (No CPR 94-696) Boehringer Ingelheim, Basel
5. Arzneimittelprüfrichtlinien vom 14.12.1989. Pharm Ind (1990) 52/1: 45-54 und 52/2: 175-178
6. Arzneimittelprüfrichtlinien vom 14.12.1989. Pharm Ind (1990) 52/1: 45-54 und 52/2: 175-178
7. Beaver WT (1984) Combination analgesics, Am J Med (Sept 10): 38-53
8. Bengtsson U (1989) Analgetika-Nephropathie - Langfristige Erfahrungen aus Schweden. Z Urol Nephrol 82 [Suppl]: 121-125
9. Bergmann K, Müller L, Weber-Teigen S (1995) The genotoxicity and carcinogenicity of paracetamol - a regulatory (re)view. Mutat Res (in press)
10. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Schreiben an den Bundesfachverband der Arzneimittelhersteller e.V. (BAH) vom 21.12.1995
11. Bippi H, Frölich JC (1990) Effects of acetylsalicyclic acid and paracetamol alone and in combination on prostanoid synthesis in man. Br J Clin Pharmacol 29: 305-310
12. Bosanquet N. Zamrnit-Lucia J (1992) Migraine: prevention or cure? Br J Med Economics 2: 81-91
13. Bosse K. Kühner A (1988) Behandlung von Kopfschmerzen verschiedenster Genese. Therapiewoche 38: 3879-3884
14. Brune K, Beck WS (1993) Nichtopioidanalgetika (antipyretische und andere). In: Zcnz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wiss Verlagsgesellschaft, Stuttgart, S 121-136
15. Brunner FP, Selwood NH (1994) End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Registry Report. Nephrol Dial Transplant 9: 1371-1376
16. Bundesgesundheitsamt (BGA) (1988) Coffein. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr. 209
17. Bundesgesundheitsamt (BGA) (1988) Paracetamol plus Coffein in fixer Kombination. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr. 209
18. Bundesgesundheitsamt (BGA) (1992) Acetylsalicylsäure. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr. 191
19. Bundesgesundheitsamt (BGA) (1993) Paracetamol. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr. 165
20. Bundesgesundheitsamt (BGA) (1994) Acetylsalicylsäure plus Coffein in fixer Kombination. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr 31
21. Bundesgesundheitsamt (BGA) (1994) Acetylsalicylsäure plus Paracetamol in fixer Kombination. Monographie der Aufbereitungskommission B-3 "Neurologie/Psychiatrie". Bundesanzeiger Nr. 88
22. Camann WR, Murray RS, Mushlin PS, Lambert DH (1990) Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg 70: 181-184
23. Cony VF, Sterbenz FJ, Mueller F, Melman K, Ederma H, Skerpac J, Hunter D, Lehr M (1977) Augmentation of human blood acetylsalicylate concentrations by the simultaneous administration of acetaminophen with aspirin. Toxicol Appl Pharmacol 41: 7-13
24. 2 purine receptors. In: Philhs JW (ed) Adenosine and adenine nucleotides as regulation of cellular function. CRC Press, Boca Raton, pp 133-140
25. Crout JR (1974) Fixed combination prescription drugs: FDA Policy. J Clin Pharmacol 14: 249-254
26. Cull RE, Wells NEJ, Micocevich ML (1992) The economic cost of misraine. Br J Med Economics 2: 103-115
27. Dahanukar SA, Pohujani S, Sheth UK (1978) Bioavailability of aspirin and interacting influence of caffeine. Indian J Med Res 68: 844-848
28. Dalessio DJ, Silberstein SD (1993) Wotffs headache and other head pain. Oxford University Press, New York Oxford
29. Dalessio DJ (1994) On the safety of caffeine as an analgesic. Adjuvant Headache Quarterly 5: 125-127
30. Derby LE, Jick H (1991) Renal parenchymal disease related to over-the-counter analgesic use. Pharmacotherapy 11: 467-471
31. Dubach UC, Rosner B, Pfister E (1983) Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 308: 357-362
32. Dubach UC, Rosner B, Stürmer T (1991) An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicy late on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 324: 155-160
33. Engelhardt G (1983) Vergleich der pharmakologischen Wirkungsprofile von Acetylsalicylsäure und Paracetamol. Ärztl Forsch 30: 1-16
34. Engelhardt G (1984) Tierexperimentelle Untersuchungen zur Frage des Zusammenwirkens von Paracetamol und Acetylsalicylsäure. Arzneimittelforschung 34/9: 992-1001
35. Engelhardt G (1985) Zur Pharmakologie der "schwachwirksamen Analgetika". In: Forth W (Hrsg) Analgetika. Zur Problematik der schwachwirksamen Analgetika. TW Taschenbuch. Bd 7. G Braun Verlag, Karlsruhe, S 100-108
36. Engelhardt G (1989) Interaktionen von Paracetamol, Acetylsalicylsäure und Coffein im akuten pharmakologischen Experiment. Unveröff Bericht, Dr. Karl Thomae GmbH. Biberach
37. 1α,Wasser-, Kreatinm- und Elektrolytausscheidung der Ratte. Arzneimittelfcrschung (im Druck)
38. Europäische Gemeinschaft (1983) Empfehlung des Rates zu den Versuchen mit Arzneispezialitäten im Hinblick auf deren Inverkehrbringen. Anderungsrichtlinie 83/571 EWG vom 26.10.1983
39. Fields HL (1987) Pain. McGraw-Hill, New York
40. Forth W (1993) Sinnvolle Medikamenten-Kombinatio-nen. In: Zenz M. Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wiss Verlagssesellschaft, Stuttgart. S 187-195
41. Fox JM (1988) Coffein plus Analgetika - eine sinnvolle Kombination. Der Schmerz 2: 183-197
42. Fox JM (1995) Kombinationsarzneimittel aus Paracetamol plus Acetylsalicylsäure: Nutzen und Risiko. Der Schmerz 9: 273-285
43. Gennaro AR, Packman EW, DeLong AF (1981) Plasma levels of aspirin and acetaminophen produced by a single combined dose of aspirin and acetaminophen in man. Am J Pharmacol 153: 12-18
44. Glissold SP (1986) Aspirin and related derivatives of salicylic acid. Drugs 32 [Suppl] 4: 8-26
45. Glissold SP (1986) Paracetamol and phenacetin. Drugs 32 [Suppl] 4: 46-59
46. Göbel H, Petersen-Braun M, Soyka D (1993) Die Prävalenz von Kopfschmerzen in Deutschland. Der Schmerz 7: 287-297
47. Göbel H (1994) Kopfschmerzen. Springer, Berlin Heidelberg New York Tokyo
48. Griffiths RR, Woodson PP (1988) Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacol 94: 437-451
49. Griffiths RR. Woodson PP (1988) Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther 246: 21-29
50. Griffiths RR, Woodson PP (1988) Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 29: 419-427
51. Grotto M, Dikstein S, Sulman FG (1965) Additive and augmentative synergism between analgesic drugs. Arch Int Pharmacodyn 155: 365-372
52. Hackenthal E (1990) Die Salicylate. Der Schmerz 4: 166-172
53. Insel PA (1990) Analgesic-antipyretics and antiinflammatory agents: Drugs employed in the treatment of rheumatoid arthritis and gout. In: Goodman Gilman A, Rail TW. Nies AS, Taylor P (eds) Goodman and Gilman's. The pharmacological basis of therapeutics, 8th edn. Pergamon Press. New York, pp 638-653/656-659
54. Interkantonale Kontrollstelle für Heilmittel (IKS) (1985) Richtlinien der IKS betreffend Anforderungen an die Dokumentation für die Registrierung von Arzneimitteln der Humanmedizin (Registrierungsrichtlinien) IKS, Bern
55. Kmcaid-Smith P (1978) Analgesic nephropathy. Kidney Int 13: 1-4
56. Kunovits G (1995) Nierenschäden durch Analgetika. Analgetika-Nephropathie Folge des genetisch bedingten Polymorphstoffwechsels von Phenazetin? Gazette Médicale/Der informierte Arzt 6: 439-441
57. Ladewig D (1985) Psychologische Aspekte der Abhängigkeit bei "schwachwirksamen Analgetika". In: Forth W (Hrsg) Analgetika. Zur Problematik der schwachwirksamen Analgetika. TW Taschenbuch Bd 7. G Braun Verlag, Karlsruhe. S 56-63
58. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A (1984) Caffeine as an analgesic adjuvant. JAMA 251: 1711-1718
59. Lehmann H, Hirsch U, Bauer E, Bauer A, Greischel A, Schneider P ( 1996) Chronical toxicity study of Thomapyrin® in rats. Arzneimittelforschung (in press)
60. Lipton RB, Solomon S, Sheftell FD (1995) Medical consultation for migraine: results from the AASH-Gallup survey. Scientific paper presentation. 37th annual scientific meeting of the american association for the study of headache, Boston. Jun 23-25
61. Marone G, Cirillo R, Genovese A, Marino O, Quanrin S (1989) Human basophil mast cell releasabilty. VII. Heteroseneity of the effect of adenosine on mediator secretion. Life Sci 45: 1745-1754
62. McAnally JF, Winchester JF, Schreiner GE (1983) Analgesic nephropathy. Arch Intern Med 143: 1897-1899
63. Menges K (1987) Paracetamol (Acetaminophen) Pharmakologie und klinische Anwendung. Der Schmerz 1: 130-134
64. Meredith TJ, Goulding R (1980) Paracetamol. Postgrad Med J 56: 459-473
65. Migliardi JR, Armellino JJ, Friedman M, Gillings DB, Beaver WT (1994) Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 56: 576-586
66. 1α-und Kreatinin-Konzentration im Urin nach 3tägiger Behandlung mit ASS 500 mg. ASS 500 mg/Coffein 100 mg 3 x täglich bei gesunden Probanden. Unveröff Bericht (IP-Nr 155.3), Boehringer Ingelheim Deutschland, Ingelheim
67. Murray TG, Stolley PD, Anthony SC (1983) Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 143: 1687
68. Nanra RS, Kmcaid-Smith P (1970) Papillary necrosis in rats caused by aspirin and aspirin containing mixtures. Br Med J 3: 559-562
69. Nanra RS (1983) Renal effects of antipyretic analgesics. Am J Med 75: 70-81
70. Needs CJ, Brooks PM (1985) Clinical pharmacokinetics of the salicylates, Clinical Pharmacokinetics 10: 164-177
71. Osterhaus JT, Guttermann DL, Plachetka JR (1992) Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 2: 67-76
72. Payne R, Max M, Inturrisi CH, Rogers A, Miser A, Perry S, Kanner R (1986) Principles of analgetic use in the treatment of acute pain and chronic cancer pain. The American Pain Society
73. Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331: 1675-1679
74. Piletta P, Porchet HC, Dayer P (1991) Distinct central nervous system involvement of paracetamol and salicylate. In: Bond MR, Charlton JE, Woolf CJ (eds) Proceedings of the VIth World Congress on Pain. Elsevier Science Publishers. Amsterdam, pp 181-184
75. Rasmussen BK, Jensen R, Olesen J (1993) Epidemiology of tension-type headache in a general population. In: Olesen J, Schoenen J (eds) Tension-type headache: classification, mechanisms, and treatment. Raven Press, New York, pp 9-13
76. Reynolds JEF (1993) Martindale - The extra pharmacopoeia, 30th edn. The monographs on drugs and ancillary substances. Analgesics and anti-inflammatory agents. The Pharmaceutical Press, London, pp 3-7/27-28
77. Robbins LD (1994) Management of headache and headache medications. Springer, New York
78. Rubin A, Winter L (1983) The study of pain in hospital patients: evaluations of an aspirin/acetaminophen combination with and without caffeine. Unpublished report (No 2196), Bristol-Myers Products, New York
79. Sagelsdorff P (1995) Paracetamol: metabolite profile in plasma, urine and feces of male Tif:RAIf rats following single and repeated oral (gavage) administration. Unveroff Bericht (CB 94/15) Dr Karl Thomae GmbH, Biberach
80. Sandier DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, Blythe WB, Burgess WP (1989) Analgesic use and chronic renal disease. N Enal J Med 320: 1238-1243
81. Sawynok J, Yaksh TL (1993) Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 45: 43-85
82. Sawynok J (1995) Pharmacological rationale for the clinical use of caffeine. Drugs 49: 37-50
83. Sawynok J, Reid AR, Doak GJ (1995) Caffeine antinociception in the rat hot-plate and formalin tests and locomotor stimulation: involvement of noradrenergic mechanisms. Pain 61: 203-213
84. Schäfer E, Richter E (1991) Akzeptanzstudie eines Coffein-haltigen Kombinationsanalgetikums gegen die Coffein-freie Kombination (doppelblinder, kontrollierter, randomisierter Cross-over-Vergleich). Unveröff Bericht Boehringer Ingelheim KG. Ingelheim
85. Schmid J, Fedorcak A, Zimmer A, Koss FW (1980) Die Pharmakokinetik eines Kombinationspräparates. Dtsch Apoth 32: 576-587
86. Schmid J, Brickl R (1985) Zur Pharmakokinetik "schwachwirksamer Analgetika". II. Pharmakokinetik eines Kombinationspräparates. In: Forth W (Hrsg) Analgetika. Zur Problematik der schwachwirksamen Analgetika. TW Taschenbuch Bd 7, G Braun Verlag, Karlsruhe, S 121-130
87. Scott DK (1990) Paracetamol Poisoning. Pharmaceut J 245: 95-97
88. Seegers AJM, Jager LP, Zandberg P, van Noordwijk J (1981) The anti-inflammatory, analgesic and antipyretic activities on non-narcotic analgesic drug mixtures in rats. Arch Int Pharmacodyn 251: 237-254
89. Stang P, Edwards CI (1995) The epidemiology and burden of migraine. Sumatriptan-Syrnposium. 1st Congress of the Europ Federation of Neurolog. Sci, Marseille, Sept 4-14
90. Stern KN, Chait LD. Johanson CE (1989) Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacol 98: 81-88
91. Strain EC, Mumford GK, Silverman K, Griffiths RR (1994) Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. JAMA 272: 1043-1048
92. Sunshine A, Roure C, Badillo S (1983) Subjective clinical evaluation of the relative potency of caffeine in combination with aspirin/acetaminophen at different doses in clinical analgesia. Unpublished report (No 2275) BristolMyers Products, New York
93. Sunshine A, Zighelboim I (1983) Subjective clinical evaluation of the relative potency of caffeine in combination with aspirin/acetaminophen at different dosis in clinical analgesia. Unpublished report (No 2276-1) Bristol-Myers Products, New York
94. lished report (No 2276-11) Bristol-Myers Products, New York
95. 3th edn. Churchill Livingstone, Edinburgh, pp 923-942
96. Taiwo YO, Levine JD (1990) Direct cutaneous hyperalgesia induced by adenosine. Neurosci 38: 757-762
97. Thomas H (1995) Paracetamol: 30 hours oral (gavage) toxicity and micronucleus study in male and female Tif:RAIf rats. Unpublished report CB 94/13 (Test No 940005), Basel
98. Thomas H (1995) Paracetamol: assessment of diagnostic biochemical markers for toxicity (time profile) in male Tif:RAIf rats following single and repeated oral (gavage) administration. Unpublished report CB 94/14 (Test No 940006), Basel
99. Tukker JJ, Sitsen JMA, Gusdorf CF (1986) Bioavailability of paracetamol after oral administration to healthy volunteers. Pharma Weekbl Sci Edn 8: 239-242
100. Valderrâbano F, Jones EHP, Mallik NP (1995) Report on management of renal failure in Europa, XXIV, 1993. Nephrol Dial Transplant 10 [Suppl] 5: 1-25
101. Vane JR. Botting RM (1985) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44: 1-10
102. Ward N, Whitney C, Avery D, Dunner D (1991) The analgesic effects of caffeine in headache. Pain 44: 151-155
103. Whitcomb DC, Block GD (1994) Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272: 1845-1850
104. Winn HR, Rubio GR, Berne RM (1981) The role of adenosine in the regulation of cerebral blood flow. J Cereb Blood Flow Metab 1: 129-133
105. Yoovathaworn KC, Sriwatanakul K, Thithapandha A (1986) Influence of caffeine on aspirin pharmakokinetics. Europ J Drug Metabolism Pharmacokin 11: 71-76